Biomerica (BMRA) AI Stock Analysis

• Market Cap: $8.45M
• Dividend Yield: N/A
• Average Volume (3M): 1.62M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.52
• Revenue Growth: -1.88%
• EPS Growth: 23.99%
• Country: US
• Employees: 64
• Sector: Healthcare
• Sector Strength: 51
• Industry: Medical - Devices
• EPS (TTM): -0.61
• Shares Outstanding: 2,815,410
• 10 Day Avg. Volume: 730,053
• 30 Day Avg. Volume: 1,620,389
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.69
• Enterprise Value/Revenue: 1.03
• Enterprise Value/Gross Profit: 7.61
• Enterprise Value/Ebitda: -1.24
• 1Y Price Target: $3.00
• Price Target Upside: 6.38% Upside
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 1

• Rating: 40 Underperform
• Price Target: $3.00 ▲(6.38% Upside)

Biomerica's overall stock score is primarily impacted by its poor financial performance and valuation. The company's financial struggles, including declining revenues and negative profitability, are significant concerns. Technical analysis also indicates bearish momentum. While the appointment of a new board member is a positive step, it does not significantly offset the financial and technical challenges.

Biomerica Business Overview & Revenue Model

Company Description

Biomerica, Inc. (BMRA) is a global biomedical technology company headquartered in Irvine, California. The company operates in the healthcare sector, focusing on the development, manufacturing, and marketing of diagnostic products designed to enhance early detection and therapeutic monitoring of medical conditions. Biomerica's core offerings include diagnostic tests in areas such as food intolerance, gastrointestinal diseases, and diabetes, among others. These tests are designed for use in clinical laboratories, physician's offices, and for over-the-counter markets.

How the Company Makes Money

Biomerica generates revenue primarily through the sale of its diagnostic and therapeutic products. The company offers a range of products targeting various medical conditions, which are sold to laboratories, hospitals, and healthcare providers. Key revenue streams include the sales of diagnostic test kits for food intolerance and gastrointestinal disorders, which are distributed both domestically and internationally. Biomerica also engages in partnerships and collaborations with other healthcare organizations and research institutions to enhance product development and expand market reach. The company aims to leverage its innovative product pipeline and global distribution network to drive sales and increase market share.

Biomerica Financial Statement Overview

Summary

Biomerica faces significant financial challenges with declining revenues and persistent losses impacting profitability and cash flow. The balance sheet is relatively stable, but reliance on external financing and negative cash flows pose risks. Strategic improvements in operational efficiency and revenue growth are needed.

Income Statement

Biomerica has experienced a decline in revenue over the past years, with a significant drop from 2022 to 2023. The gross profit margin is low, indicating high production costs relative to revenue. The company has been operating at a loss, with negative EBIT and EBITDA margins, suggesting operational inefficiencies. However, there is a slight improvement in net income from 2023 to 2024, indicating potential for recovery.

Balance Sheet

The balance sheet shows a moderate debt-to-equity ratio, suggesting manageable leverage levels. The equity ratio is relatively healthy, indicating a solid capital structure. However, the declining stockholders' equity over the years is a concern. The return on equity is negative due to consistent net losses, highlighting profitability challenges.

Cash Flow

Biomerica's cash flow statement reveals negative operating cash flow, indicating cash outflows from core operations. The free cash flow is also negative, reflecting challenges in generating cash after capital expenditures. The company has relied on financing activities to support cash needs, which may not be sustainable long-term.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	5.31M	5.42M	5.34M	18.87M	7.20M
Gross Profit	498.00K	611.00K	446.00K	2.98M	496.98K
EBITDA	-4.74M	-5.99M	-6.74M	-3.94M	-7.06M
Net Income	-4.97M	-5.98M	-7.14M	-4.53M	-6.47M
Balance Sheet
Total Assets	5.95M	9.25M	14.45M	11.37M	11.82M
Cash, Cash Equivalents and Short-Term Investments	2.40M	4.17M	9.72M	5.92M	4.20M
Total Debt	458.00K	785.00K	1.08M	1.38M	1.62M
Total Liabilities	1.84M	2.66M	2.73M	3.05M	2.59M
Stockholders Equity	4.11M	6.59M	11.72M	8.32M	9.23M
Cash Flow
Free Cash Flow	-3.88M	-5.48M	-5.55M	-650.87K	-5.55M
Operating Cash Flow	-3.84M	-5.36M	-5.47M	-480.53K	-5.25M
Investing Cash Flow	-37.00K	-115.00K	-78.00K	-170.34K	-295.58K
Financing Cash Flow	2.11M	-81.00K	9.39M	2.39M	1.11M

Biomerica Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.82
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BMRA, the sentiment is Negative. The current price of 2.82 is below the 20-day moving average (MA) of 3.14, below the 50-day MA of 3.26, and below the 200-day MA of 3.75, indicating a bearish trend. The MACD of -0.09 indicates Positive momentum. The RSI at 38.23 is Neutral, neither overbought nor oversold. The STOCH value of 18.92 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BMRA.

Biomerica Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.91B	-0.36	-41.71%	2.23%	23.45%	-1.86%
PAVM	51 Neutral	$9.60M	0.38	-499.57%	―	-73.36%	―
VVOS	48 Neutral	$33.02M	―	-262.03%	―	2.65%	70.21%
SSKN	47 Neutral	$7.09M	―	-235.41%	―	0.36%	-17.20%
NURO	45 Neutral		―		―	-48.61%	32.18%
CODX	45 Neutral	$11.90M	―	-63.40%	―	-91.14%	9.47%
BMRA	40 Underperform	$8.45M	―	-92.99%	―	-1.88%	23.99%

Biomerica Corporate Events

Biomerica Appoints Eric B. Chin to Board

On June 4, 2025, Cathy Coste resigned from Biomerica‘s Board of Directors, and Eric B. Chin was appointed as an independent member, serving as Chairperson of the Audit Committee. Mr. Chin, an experienced financial executive, is expected to strengthen Biomerica’s corporate governance and financial oversight as the company scales its commercialization efforts. His extensive background in healthcare finance, including his role as CFO of Akido Labs, positions him to contribute significantly to Biomerica’s strategic objectives.